89BIO (ETNB) Competitors $10.14 +0.04 (+0.40%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$10.14 -0.01 (-0.05%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ETNB vs. TGTX, LNTH, NUVL, TLX, AXSM, ADMA, AKRO, PCVX, RYTM, and KRYSShould you be buying 89BIO stock or one of its competitors? The main competitors of 89BIO include TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. 89BIO vs. Its Competitors TG Therapeutics Lantheus Nuvalent Telix Pharmaceuticals Axsome Therapeutics ADMA Biologics Akero Therapeutics Vaxcyte Rhythm Pharmaceuticals Krystal Biotech 89BIO (NASDAQ:ETNB) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Which has stronger valuation & earnings, ETNB or TGTX? TG Therapeutics has higher revenue and earnings than 89BIO. 89BIO is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89BION/AN/A-$367.08M-$3.38-3.00TG Therapeutics$329M17.95$23.38M$0.24155.00 Do analysts prefer ETNB or TGTX? 89BIO currently has a consensus price target of $26.43, indicating a potential upside of 160.64%. TG Therapeutics has a consensus price target of $40.80, indicating a potential upside of 9.68%. Given 89BIO's stronger consensus rating and higher possible upside, equities analysts clearly believe 89BIO is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89BIO 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media favor ETNB or TGTX? In the previous week, TG Therapeutics had 5 more articles in the media than 89BIO. MarketBeat recorded 5 mentions for TG Therapeutics and 0 mentions for 89BIO. TG Therapeutics' average media sentiment score of 0.84 beat 89BIO's score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 89BIO Neutral TG Therapeutics Positive Is ETNB or TGTX more profitable? TG Therapeutics has a net margin of 10.13% compared to 89BIO's net margin of 0.00%. TG Therapeutics' return on equity of 18.88% beat 89BIO's return on equity.Company Net Margins Return on Equity Return on Assets 89BION/A -81.44% -70.17% TG Therapeutics 10.13%18.88%7.05% Do insiders and institutionals believe in ETNB or TGTX? 58.6% of TG Therapeutics shares are owned by institutional investors. 2.8% of 89BIO shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ETNB or TGTX? 89BIO has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. SummaryTG Therapeutics beats 89BIO on 12 of the 15 factors compared between the two stocks. Get 89BIO News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ETNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETNB vs. The Competition Export to ExcelMetric89BIOMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.48B$2.89B$5.53B$9.02BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-3.0021.7127.7020.25Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book3.047.538.035.65Net Income-$367.08M-$55.14M$3.18B$249.15M7 Day Performance3.26%4.22%2.88%2.91%1 Month Performance-1.07%0.91%1.67%4.11%1 Year Performance34.84%5.40%34.39%20.98% 89BIO Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETNB89BIO1.5652 of 5 stars$10.14+0.4%$26.43+160.6%+34.8%$1.48BN/A-3.0040TGTXTG Therapeutics3.2906 of 5 stars$35.99-2.0%$40.80+13.4%+95.7%$5.71B$386.39M149.96290LNTHLantheus4.4551 of 5 stars$81.86+0.5%$130.50+59.4%+0.4%$5.66B$1.53B23.26700Positive NewsNUVLNuvalent3.7239 of 5 stars$76.30-4.2%$119.60+56.7%+10.3%$5.48BN/A-17.3840TLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.44B$516.72M0.00N/AAXSMAxsome Therapeutics4.7484 of 5 stars$104.39+1.0%$172.33+65.1%+28.5%$5.14B$432.16M-18.09380Trending NewsADMAADMA Biologics4.1503 of 5 stars$18.21+0.3%$27.67+51.9%+59.6%$4.35B$426.45M21.42530Positive NewsAKROAkero Therapeutics3.4504 of 5 stars$53.36-5.0%$82.50+54.6%+142.5%$4.25BN/A-27.3630PCVXVaxcyte1.7706 of 5 stars$32.51-0.2%$136.50+319.9%-57.3%$4.19BN/A-8.15160RYTMRhythm Pharmaceuticals3.8195 of 5 stars$63.19+0.7%$77.31+22.3%+55.6%$4.02B$136.86M-22.49140KRYSKrystal Biotech4.5875 of 5 stars$137.46-1.0%$211.13+53.6%-22.4%$3.97B$333.45M33.04210 Related Companies and Tools Related Companies TG Therapeutics Alternatives Lantheus Alternatives Nuvalent Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives ADMA Biologics Alternatives Akero Therapeutics Alternatives Vaxcyte Alternatives Rhythm Pharmaceuticals Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETNB) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89BIO Please log in to your account or sign up in order to add this asset to your watchlist. Share 89BIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
